Gelonghui, March 1, 丨 Salen Biotech (688163.SH) recently said during a survey receiving institutional investors that the company's rapid snake venom diagnostic reagent research and development project is based on clinical snake venom diagnosis and treatment needs, the company's advantages of being deeply involved in the snake wound first aid market over many years, and years of research accumulation and technical advantages on snake venom toxins. Currently, treatment of snake injuries is still limited to testing toxins based on the general appearance of the attacking snake, the patient's wound, snake tooth bite marks, or external laboratory tests to determine what kind of poisonous snake bite it is, and then take corresponding treatment measures. There is still a lack of direct, quick, and effective technical diagnostic measures to identify what kind of snake injury it is.
Currently, the company is developing rapid diagnostic reagents for cobra venom, viper venom, and five-step snake venom. The reagent uses colloidal gold technology to interpret and test by injecting the sample solution into the test card to observe whether a red line appears at the location of the test line, so as to provide doctors and patients with test reagents with high sensitivity, good specificity, convenient and quick, and direct and clear interpretation of results to ensure the selection of correct drugs and treatment plans in the first aid for patients with snake injuries, and save valuable time to save patients' lives. At the same time, it can also be used to track the toxic conditions in the body during treatment. Clinical judgment on whether to return Increased application of anti-snake venom serum is needed.
